Arana completes Phase II
Monday, 09 March, 2009
Arana Therapeutics, currently the subject of a takeover bid by US company Cephalon, has completed its Phase II trial of lead candidate ART621 in psoriasis.
The trial met the primary endpoints of tolerability and safety. Secondary findings included evidence of anti-tumour necrosis factor activity, a reduction in severity in some patients and no antibody responses against the drug, suggesting the drug has low immunogenicity, the company said.
ART621 is a human domain-based antibody directed against TNF. It is currently in two Phase II trials for rheumatoid arthritis in combination with methotrexate.
The study was conducted at the Nucleus Network in Melbourne and CMAX in Adelaide.
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
'Anti-reward' brain network helps explain cocaine addiction
A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...
Intense grief linked to higher risk of death for a decade
Researchers have found that bereaved people with persistent high levels of intense grief use more...
